IQVIA Inc.
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences indust...
Latest News
5 days ago · marketbeat.com
What IQVIA (IQV) Said on Its Q3 Earnings CallIQVIA NYSE: IQV reported third-quarter results that exceeded the high end of its guidance ranges, supported by accelerating organic growth in its Commercial Solutions and R&D Solutions businesses, higher clinical win rates and strong free cash flow.
6 days ago · zacks.com
IQVIA Holdings Q3 Earnings Beat Estimates, Revenues Increase 8% Y/YIQV's Q3'26 earnings beat estimates as revenues rise 8% y/y, led by strong clinical demand, robust R&D bookings and improved execution, prompting a view hike.
6 days ago · zacks.com
IQVIA Holdings (IQV) Surpasses Q3 Earnings and Revenue EstimatesIQVIA Holdings (IQV) came out with quarterly earnings of $3.34 per share, beating the Zacks Consensus Estimate of $3.24 per share. This compares to earnings of $3 per share a year ago.
11 days ago · zacks.com
IQVIA Gears Up to Post Q3 Earnings: Here's What Investors Should KnowIQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.
13 days ago · seekingalpha.com
IQVIA: R&D Bookings Are Reaccelerating, But The Valuation Now Requires ExecutionIQVIA Holdings (IQV) is rated Buy, supported by strong Q2 results and a robust R&D bookings recovery. Q2 revenue grew 8.7% to $4.37B, with adjusted EPS up 12.1% and R&D net new bookings surging 19% to $3.15B. Commercial Solutions delivered 8.6% revenue growth, with AI adoption and data assets driving margin expansion and cross-selling opportunities.
13 days ago · zacks.com
IQVIA Holdings (IQV) Earnings Expected to Grow: Should You Buy?IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
25 days ago · zacks.com
Here's Why IQVIA Holdings (IQV) is a Strong Momentum StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
1 month ago · zacks.com
Extensive Database & Solid Bookings Benefit IQVIA Amid Low LiquidityIQV's vast healthcare database, AI-enabled capabilities and strong R&DS bookings support growth, while low liquidity and $14.1B net debt remain in focus.
2 months ago · zacks.com
IQVIA Stock Rises 60% in 6 Months: Here's What You Should KnowIQV's accelerating organic growth, robust R&DS bookings and expanding AI adoption are strengthening demand visibility and business momentum.
2 months ago · zacks.com
Why IQVIA Holdings (IQV) is a Top Momentum Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove IQV